Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)

Condition(s) targeted: Asthma

Intervention: Beclomethasone dipropionate (Drug); Beclomethasone dipropionate (Drug); Albuterol sulfate (Drug)

Phase: Phase 3

Status: Recruiting

Sponsored by: National Heart, Lung, and Blood Institute (NHLBI)

Official(s) and/or principal investigator(s):
David T. Mauger, PhD, Principal Investigator, Affiliation: Penn State College of Medicine
Stanley J. Szefler, MD, PhD, Principal Investigator, Affiliation: National Jewish Medical and Research Center
Robert F. Lemanske, Jr., MD, Principal Investigator, Affiliation: University of Wisconsin, Madison
Robert S. Zeiger, MD, PhD, Principal Investigator, Affiliation: Kaiser Permanente Medical Center
Robert C. Strunk, MD, Principal Investigator, Affiliation: Washington University School of Medicine
Fernando D. Martinez, MD, Principal Investigator, Affiliation: University of Arizona College of Medicine
Lynn M. Taussig, MD, Study Chair, Affiliation: University of Denver

Asthma is a common, serious illness among children in the United States. It can be effectively controlled through the use of preventative medications and "rescue" medications, which are used to control symptoms. This study will evaluate the impact and severity of asthma exacerbations that occur in children with mild persistent asthma who are receiving various combinations of medications for daily and rescue use.

Official title: Childhood Asthma Research and Education (CARE) Network Trial - Treating Children to Prevent Exacerbations of Asthma (TREXA)

Study design: Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study

Primary outcome: Time to asthma exacerbation requiring systemic corticosteroid therapy

Secondary outcome:

Asthma control days

Albuterol use

Spirometry, pre- and post-bronchodilator

AM and PM peak expiratory flow rate

Peak expiratory flow rate variability

Impulse oscillometry

Methacholine PC20

Exhaled nitric oxide

Asthma-specific quality of life assessment

Asthma control test

Adverse events

Detailed description: Almost 9 million children in the United States have asthma, and it is a leading cause of hospitalizations and school absenteeism. Common asthma symptoms include wheezing, shortness of breath, chest tightness, and coughing. While there is no cure for asthma, most children who receive proper treatment are able to control symptoms and lead a normal life. Asthma is commonly treated with two types of medications: long-term control medication, such as inhaled corticosteroids (ICS), which is taken on a regular schedule to prevent symptoms and keep asthma under control, and quick-relief, or "rescue" medication, such as albuterol, which is used on an as-needed-basis with the onset of symptoms or an asthma attack. The purpose of this study is to assess the impact and severity of asthma exacerbations that occur in children with mild persistent asthma who are receiving ICS on a daily basis plus ICS and albuterol as rescue medications.

This study will begin with a 4-week screening period during which participants will be monitored while they use an inhaler with a low dose of ICS medication. Study visits will occur at study entry and Week 4. Participants will undergo a physical examination, lung function and airway pressure testing, and blood collection. At the Week 4 study visit, participants will be randomly assigned to one of the following four groups for 44 weeks of treatment:

- Group 1 will take ICS twice a day and ICS plus albuterol as rescue medication

- Group 2 will take ICS twice a day and placebo ICS plus albuterol as rescue medication

- Group 3 will take placebo ICS twice a day and ICS plus albuterol as rescue medication

- Group 4 will take placebo ICS twice a day and placebo ICS plus albuterol as rescue

medication

Each participant will receive three inhalers with their assigned medication. One inhaler will be used twice daily throughout the study. The other two inhalers will be used consecutively on an as-needed-basis as rescue medication. Study visits will occur at Weeks 8, 16, 24, 32, 40, and 48. A physical examination, blood collection, and lung function and airway pressure testing will occur at selected visits. Questionnaires to assess quality of life and asthma control will also be completed. A methacholine challenge test will be completed at some study visits. This test artificially triggers an asthma attack to determine the severity of an individual's asthma. Throughout the study, participants will record asthma symptoms and rescue medication usage in a daily diary.

Minimum age: 6 Years. Maximum age: 18 Years. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Able to perform reproducible spirometry according to American Thoracic Society (ATS)

criteria

- History of asthma symptoms that are adequately controlled in the 4 weeks prior to

study entry, and meets at least one of the following criteria:

1. History of mild persistent asthma symptoms (on average greater than 2 days per week with symptoms or albuterol use for symptoms or greater than 2 night-time awakenings per month during the year prior to study entry) and has been treated with a single-controller ICS dose less than or equal to 160 mcg per day of a beclomethasone-equivalent or a LTRA (in an age-appropriate dose) for the 4 weeks prior to study entry; individuals treated with a combination controller therapy (e. g. ICS+LTRA or ICS+LABA) in the past 8 weeks will not be eligible

2. Not currently being treated with ICS, a history of mild persistent asthma, and 1 to 2 exacerbations in the year prior to study entry (but none in the 3 months prior to study entry)

- FEV1 reversibility of greater than or equal to 12% following bronchodilator

administration (4 puffs); individuals who do not meet this requirement may qualify for enrollment if their PC20 methacholine FEV1 is less than or equal to 12. 5 mg/ml

- History of clinical varicella or varicella vaccine; individuals needing the vaccine

may receive it from their primary care physician prior to study entry

- Ability of parent to provide informed consent; verbal assent must be obtained from

children less than 7 years of age and written assent must be obtained from children between 7 and 18 years of age

- If female, willing to use an effective form of contraception

Participants will be eligible for the 44 weeks of treatment if, after the 4-week screening period, their asthma remains controlled, and they demonstrate at least 80% predicted pre-bronchodilator FEV1. Participants must meet ALL of the criteria stated below during the 8-week screening period to continue in the study:

- Meets the definition of acceptable asthma control, which is NOT having one or more of

the following during ANY 2-week period:

1. On average, on more than 2 days per week, experiences one or more of the following:

1. Diary-reported symptoms

2. The use of inhaled bronchodilator (not including pre-exercise)

3. Peak flows in the yellow zone (less than 80% of personal best defined as based on PEF value obtained at study visit 1

2. More than 1 night-time awakening due to asthma

- Demonstrates adherence with taking study medications (at least 75% of scheduled

doses), rescue medications (using both rescue inhalers for at least 75% of rescue doses), and completing patient diaries (at least 75% of days)

- Pre-bronchodilator FEV1 greater than or equal to 80% predicted at study visits 2 and

3

- Agrees to not use a spacer with beclomethasone/placebo study and rescue medications

Exclusion Criteria:

- Corticosteroid treatment for any condition prior to study entry within the following

defined timepoints:

1. Oral - Use within 2-week period of the screening visit

2. Injectable - Use within 2-week period of the screening visit

3. Nasal corticosteroids may be used at any time during the study at the discretion of the study investigator or primary care physician

- Current or prior use of medications known to significantly interact with

corticosteroid disposition (within a 2-week period of study visit 1), including but not limited to carbamazepine, erythromycin or other macrolide antibiotics, phenobarbital, phenytoin, rifampin, or ketoconazole

- Pre-bronchodilator FEV1 less than 60% predicted at study visit 1

- Any hospitalization for asthma in the year prior to study entry

- Presence of chronic or active lung disease other than asthma

- Significant medical illness other than asthma, including thyroid disease, diabetes

mellitus, Cushing's disease, Addison's disease, hepatic disease, or concurrent medical problems that could require oral corticosteroids during the study

- History of cataracts, glaucoma, or any other medical disorder associated with an

adverse effect to corticosteroids

- Any asthma exacerbation in the past 3 months or more than 2 in the past year.

- History of a life-threatening asthma exacerbation requiring intubation, mechanical

ventilation, or resulting in a hypoxic seizure

- History of adverse reactions to ICS preparations or any of its ingredients

- Receiving hyposensitization therapy other than an established maintenance regimen

(continuous regimen for at least 3 months)

- Pregnant or breastfeeding

- Cigarette smoking or smokeless tobacco use in the year prior to study entry

- Refusal to consent to a genotype evaluation

- Current participation or participation within 1 month of study entry in another

investigational drug trial

- Evidence that the family may be unreliable or nonadherent, or may move from the

clinical center area before study completion

University of Arizona College of Medicine, Tucson, Arizona 85724, United States; Recruiting
Fernando D. Martinez, MD, Phone: 520-626-6387, Email: fernando@resp-sci.arizona.edu
Wayne Morgan, MD, Phone: 520-626-7780, Email: wmorgan@resp-sci.arizona.edu
Fernando D. Martinez, MD, Principal Investigator

Kaiser Permanente Medical Center, San Diego, California 92111, United States; Recruiting
Robert S. Zeiger, MD, PhD, Phone: 858-573-5408, Email: robert.s.zeiger@kp.org
Gregory P. Heldt, MD, Phone: 619-543-3790, Email: gheldt@ucsd.edu
Robert S. Zeiger, MD, PhD, Principal Investigator

Los Angeles, Kaiser Permanente Allergy Department, Los Angeles, California 90027, United States; Recruiting
Michael S. Kaplan, MD, Phone: 323-783-4642, Email: michael.s.kaplan@kp.org
Michael S. Kaplan, MD, Sub-Investigator

National Jewish Medical and Research Center, Denver, Colorado 80206, United States; Recruiting
Stanley J. Szefler, MD, PhD, Phone: 303-398-1193, Email: szeflers@njc.org
Gary Larsen, MD, Phone: 303-398-1617, Email: larseng@njc.org
Stanley J. Szefler, MD, PhD, Principal Investigator

Washington University School of Medicine, St. Louis, Missouri 63110, United States; Recruiting
Robert C. Strunk, MD, Phone: 341-454-2284, Email: strunk@kids.wustl.edu
Leonard Bacharier, MD, Phone: 314-454-4233, Email: bacharier_l@kids.wustl.edu
Robert C. Strunk, MD, Principal Investigator

University of Wisconsin - Madison, Madison, Wisconsin 53792-3244, United States; Recruiting
Robert F. Lemanske, Jr., MD, Phone: 608-265-2206, Email: rfl@medicine.wisc.edu
Christine A. Sorkness, PharmD, Phone: 608-263-2866, Email: sorkness@facstaff.wisc.edu
Robert F. Lemanske, Jr., MD, Principal Investigator

Click here for the Childhood Asthma Research and Education (CARE) Network web site

Starting date: November 2006
Ending date: May 2010
Last updated: July 28, 2008